James Haim I. Bicher

James Haim I. Bicher (born May 12, 1937 in San Cristóbal, Santa Fe, Argentina) is an American radiation oncologist. He is a pioneer in the clinical use of hyperthermia combined with low dose (protracted) radiation therapy (thermoradiotherapy). He is a founder and past president of ISOTT,[1] North American Hyperthermia Group, and the American Society of Clinical Hyperthermic Oncology. Bicher was a student of Bernardo Alberto Houssay, and one of the contributors to the basic principles that allowed later development of Plavix.[2]

James Haim I. Bicher
Born (1937-05-12) May 12, 1937
San Cristóbal, Santa Fe, Argentina
Medical career
ProfessionRadiation Oncologist

Medical board discipline

The Medical Board of California has disciplined Bicher three times. In 1995, the Board placed him on probation for 18 months.[3] In 2004, in response to new charges, Bicher was placed on five years' probation. In 2006, in response to a new accusation, Bicher admitted no wrongdoing but agreed to have his probationary period extended by two years. In 2009, an Administrative Law judge granted Bicher's requested to have his probationary period terminated early.[4]

References
  1. Bruley, Duane Frederick (2008). ISOTT: Roots, Founding and Beyond (Oxygen Transport to Tissue XXIX). Advances In Experimental Medicine And Biology. 614. pp. 1–8. doi:10.1007/978-0-387-74911-2_1. ISBN 978-0-387-74910-5. PMID 18290308.
  2. Bicher, Haim (1972). Blood Cell Aggregation in Thrombotic Processes. Springfield: Charles C. Thomas. ISBN 9780398022327.
  3. "Medical Disciplinary Actions". Los Angeles Times. 1997-10-14. Retrieved 2019-09-30.
  4. "Accusation against Haim Bicher, M.D." www.casewatch.net. Retrieved 2019-09-30.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.